Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.

Internet Explorer 10, Firefox, Chrome, or Safari.

Volunteer Advocate
cf insights cf insights

Funding decision for ORKAMBI™ Delayed

The Canadian Agency for Drugs and Technologies in Health (CADTH) announced today that the submission for ORKAMBI™ (lumacaftor/ivacaftor) will be reconsidered at an upcoming meeting of the Canadian Expert Drug Committee (CDEC).

The Potential to Change Lives

ORKAMBI™ is a new medication indicated for people with cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation. Clinical trials indicate that ORKAMBI™ can improve lung function and reduce the number of pulmonary exacerbations, which can lead to frequent hospitalizations and accelerated lung disease.

“My daughter was fortunate enough to participate in a clinical trial for ORKAMBI™. We have seen a dramatic improvement in her lung function and a reduction in her infections and illnesses – which is hugely important for people with CF,” said Ron Anderson, the father of a 15-year-old girl living with CF. “We feel ORKAMBI™ has arrested the progression of the disease. We were hopeful that we could plan for the future in a way that we previously couldn’t. This news is certainly a setback.”

The Time is Now

We are urging decision-makers to act quickly. Cystic Fibrosis Canada is calling for the reconsideration of ORKAMBI™ to happen at the earliest opportunity, which is the next CDEC meeting in September. Cystic Fibrosis Canada, who made a submission to CADTH’s CDEC regarding ORKAMBI™, is also calling on the CDEC to carefully consider the recommendations for the clinical use of ORKAMBI™ that were developed by Cystic Fibrosis Canada’s CF Physician Panel on lumacaftor/ivacaftor endorsed by 26 CF physicians across Canada.

Raise your voice, join the #accesstomedicines conversation on Twitter

 

share
Share